Literature DB >> 11296269

In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa.

P B Robbins1, Q Lin, J B Goodnough, H Tian, X Chen, P A Khavari.   

Abstract

The blistering disorder, lethal junctional epidermolysis bullosa (JEB), can result from mutations in the LAMB3 gene, which encodes laminin 5 beta3 (beta3). Appropriate expression of LAMbeta3 in JEB skin tissue could potentially ameliorate the symptoms of the underlying disease. To explore the utility of this therapeutic approach, primary keratinocytes from six unrelated JEB patients were transduced with a retroviral vector encoding beta3 and used to regenerate human skin on severe combined immunodeficient (SCID) mice. Tissue regenerated from beta3-transduced JEB keratinocytes produced phenotypically normal skin characterized by sustained beta3 expression and the formation of hemidesmosomes. Additionally, beta3 gene transfer corrected the distribution of a number of important basement membrane zone proteins including BPAG2, integrins beta4/beta1, and laminins alpha3/gamma2. Skin produced from beta3-negative (beta3[-]) JEB cells mimicked the hallmarks of the disease state and did not exhibit any of the aforementioned traits. Therefore, by effecting therapeutic gene transfer to beta3-deficient primary keratinocytes, it is possible to produce healthy, normal skin tissue in vivo. These data support the utility of gene therapy for JEB and highlight the potential for gene delivery in the treatment of human genetic skin disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296269      PMCID: PMC33186          DOI: 10.1073/pnas.091484998

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation.

Authors:  M Gonzales; K Haan; S E Baker; M Fitchmun; I Todorov; S Weitzman; J C Jones
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

2.  Characterization of a tight molecular complex between integrin alpha 6 beta 4 and laminin-5 extracellular matrix.

Authors:  J Falk-Marzillier; S Z Domanico; A Pelletier; L Mullen; V Quaranta
Journal:  Biochem Biophys Res Commun       Date:  1998-10-09       Impact factor: 3.575

Review 3.  Severe congenital ichthyosis of the neonate.

Authors:  M Akiyama
Journal:  Int J Dermatol       Date:  1998-10       Impact factor: 2.736

Review 4.  Structure and assembly of hemidesmosomes.

Authors:  J C Jones; S B Hopkinson; L E Goldfinger
Journal:  Bioessays       Date:  1998-06       Impact factor: 4.345

5.  Optimised retroviral infection of human epidermal keratinocytes: long-term expression of transduced integrin gene following grafting on to SCID mice.

Authors:  L Levy; S Broad; A J Zhu; J M Carroll; I Khazaal; B Péault; F M Watt
Journal:  Gene Ther       Date:  1998-07       Impact factor: 5.250

Review 6.  Human gene therapy.

Authors:  W F Anderson
Journal:  Nature       Date:  1998-04-30       Impact factor: 49.962

Review 7.  Gene therapy for genetic skin disease.

Authors:  P A Khavari
Journal:  J Invest Dermatol       Date:  1998-04       Impact factor: 8.551

8.  Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells.

Authors:  P B Robbins; D C Skelton; X J Yu; S Halene; E H Leonard; D B Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  Hemidesmosome formation is initiated by the beta4 integrin subunit, requires complex formation of beta4 and HD1/plectin, and involves a direct interaction between beta4 and the bullous pemphigoid antigen 180.

Authors:  R Q Schaapveld; L Borradori; D Geerts; M R van Leusden; I Kuikman; M G Nievers; C M Niessen; R D Steenbergen; P J Snijders; A Sonnenberg
Journal:  J Cell Biol       Date:  1998-07-13       Impact factor: 10.539

10.  Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator.

Authors:  L E Goldfinger; M S Stack; J C Jones
Journal:  J Cell Biol       Date:  1998-04-06       Impact factor: 10.539

View more
  31 in total

1.  In vivo assessment of gene delivery to keratinocytes by lentiviral vectors.

Authors:  Ulrich Kuhn; Atsushi Terunuma; Wolfgang Pfutzner; Ruth Ann Foster; Jonathan C Vogel
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  c-Jun promotes whereas JunB inhibits epidermal neoplasia.

Authors:  Jane Y Jin; Hengning Ke; Russell P Hall; Jennifer Y Zhang
Journal:  J Invest Dermatol       Date:  2011-02-03       Impact factor: 8.551

3.  Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro.

Authors:  Olga Igoucheva; Aislinn Kelly; Jouni Uitto; Vitali Alexeev
Journal:  J Invest Dermatol       Date:  2007-12-13       Impact factor: 8.551

4.  The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.

Authors:  Hengning Ke; Rebecca Harris; Jonathan L Coloff; Jane Y Jin; Benjamin Leshin; Paula Miliani de Marval; Shiying Tao; Jeffrey C Rathmell; Russell P Hall; Jennifer Y Zhang
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

5.  Nucleus pulposus cell-matrix interactions with laminins.

Authors:  C L Gilchrist; A T Francisco; G E Plopper; J Chen; L A Setton
Journal:  Eur Cell Mater       Date:  2011-06-20       Impact factor: 3.942

6.  Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa.

Authors:  Vadim Lincoln; Jon Cogan; Yingping Hou; Michaela Hirsch; Michelle Hao; Vitali Alexeev; Michele De Luca; Laura De Rosa; Johann W Bauer; David T Woodley; Mei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-26       Impact factor: 11.205

7.  Host immune responses in ex vivo approaches to cutaneous gene therapy targeted to keratinocytes.

Authors:  Z Lu; S Ghazizadeh
Journal:  Exp Dermatol       Date:  2005-10       Impact factor: 3.960

Review 8.  Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Authors:  Christopher Perdoni; Mark J Osborn; Jakub Tolar
Journal:  Transl Res       Date:  2015-05-27       Impact factor: 7.012

9.  Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.

Authors:  Susana Ortiz-Urda; Qun Lin; Cheryl L Green; Douglas R Keene; M Peter Marinkovich; Paul A Khavari
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK.

Authors:  Jennifer Y Zhang; Cheryl L Green; Shiying Tao; Paul A Khavari
Journal:  Genes Dev       Date:  2004-01-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.